New insights into schizophrenia from neuroimaging

Current Opinion in Psychiatry

Volumn 11, Issue 1, 1998, Pages 33-37

  Zipursky, Robert B ^a,b   Kapur, Shitij ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT;

BRAIN BLOOD FLOW; BRAIN METABOLISM; DISEASE COURSE; DOPAMINE RELEASE; EXTRAPYRAMIDAL SYMPTOM; GRAY MATTER; HALLUCINATION; HUMAN; LONGITUDINAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031974611     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-199801000-00016     Document Type: Review

References (44)

1. Lim KO, Sullivan EV, Zipursky RB, Pfefferbaum A. Cortical gray matter volume deficits in schizophrenia: a replication. Schizophr Res 1996; 20:157-164. Although deficits in cortical gray matter volume were present in multiple cortical areas, this paper also replicates the finding of an anterior to posterior gradient in the magnitude of the deficits, with frontal and temporal regions showing greater deficits than parietal and occipital areas.
2. Lim KO, Tew W, Kushner M, Chow K, Matsumoto B, DeLisi LE. Cortical gray matter deficit is present in first episode schizophrenics. Am J Psychiatry 1996; 153:1548-1553. The magnitude of the deficits in cortical gray matter volume reported in this study are much smaller than those reported in samples of patients with chronic schizophrenia. It remains to be determined whether this can be explained by some degree of progression of the brain abnormalities in the early phase of the illness or is more likely the result of a selection bias.
3. Lim K, Harris D, Beal M, Hoff AL, Minn K, Csernansky JG, et al. Gray matter deficits in young onset schizophrenia are independent of age of onset. Biol Psychiatry 1996; 40:4-13. This MRI study involves a unique sample of 57 patients hospitalized in a California state hospital, including 21 patients whose onset of psychosis was between the ages of 7 and 14 years. Although the group as a whole had striking deficits in gray matter volumes, no association was found between the magnitude of the deficits and either the age of onset (range 7-29 years) or the duration of illness (range 4-40 years). This study provides no evidence for progression of brain abnormalities over the long-term course of the illness, but it does suggest that more severely affected individuals may have brain abnormalities of greater magnitude.
4. Woods B, Yurgelun-Todd D, Goldstein JM, Seidman LJ, Tsuang MT. MRI brain abnormalities in chronic schizophrenia: one process or more? Biol Psychiatry 1996; 40:585-596. This MRI study found significant intracranial volume reduction only in frontal lobes but evidence of relative tissue loss in all major regions assessed. This article includes a particularly thoughtful discussion dealing with the question of whether the MRI findings in schizophrenia can be best explained as the result of a single process or multiple processes.
5. Zipursky R, Seeman MV, Bury A, Langevin R, Wortzman G, Katz R. Deficits in gray matter volume are present in schizophrenia but not bipolar disorder. Schizophr Res 1997; 26:85-92. Patients with schizophrenia were shown to have deficits in gray matter volumes in multiple brain regions relative both to control individuals and to patients with bipolar disorder. This finding is consistent with previous studies and suggests that changes in the cortex might provide clues to the neuropathology that underlies schizophrenia.
6. Barta P, Pearlson GD, Brill LB, Royall H, McGilchrist IK, Pulver AE, et al. Planum temporale asymmetry reversal in schizophrenia: replication and relationship to gray matter abnormalities. Am J Psychiatry 1997; 154:661-667.
7. Zipursky RB, Lim KO, Sullivan EV, Brown BW, Pfefferbaum A. Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry 1992; 49:195-205.
8. Schlaepfer T, Harris GJ, Tien AY, Peng LW, Lee S, Federman EB, et al. Decreased regional cortical gray matter volume in schizophrenia. Am J Psychiatry 1994; 151:842-848.
9. Harvey I, Persaud R, Ron MA, Baker G, Murray RM. Volumetric MRI measurements in bipolars compared with schizophrenics and healthy controls. Psychol Med 1994; 24:689-699.
10. Arnold S, Trojanowski JQ. Recent advances in defining the neuropathology of schizophrenia. Acta Neuropathol 1996; 3:217-231.
11. Frazier J, Giedd JN, Hamburger SD, Albus KE, Kaysen D, Vaituzis AC, et al. Brain anatomic magnetic resonance imaging in childhood-onset schizophrenia. Arch Gen Psychiatry 1996; 53:617-624. This unique study of 21 patients with childhood-onset schizophrenia found reduced cerebral volume and thalamic area and enlarged basal ganglia structures, as has been reported in studies of adult-onset schizophrenia. These findings are interpreted as suggesting continuity between childhood-onset and adult-onset schizophrenia.
12. Alaghband-Rad J, Hamburger SD, Giedd JN, Frazier JA, Rapoport JL. Childhood-onset schizophrenia: biological markers in relation to clinical characteristics. Am J Psychiatry 1997; 154:64-68. This study of the clinical correlates of structural brain abnormalities in childhood-onset schizophrenia found a strong inverse correlation between total cerebral volume and negative symptoms.
13. Walker E, Lewine RJ. Prediction of adult-onset schizophrenia from childhood home movies of the patients. Am J Psychiatry 1990; 147:1052-1056.
14. Done DJ, Crow TJ, Johnstone EC, Sacker A. Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. Br Med J 1994; 309:699-703.
15. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler S, Mayerhoff D, Lieberman JA. Neuropsychological deficits in the early course of first episode schizophrenia. Schizophr Res 1991; 5:198-199.
16. Jones P, Bebbington P, Foerster A, Lewis SW, Murray RM, Russell A, et al. Premorbid social underachievement in schizophrenia - results from the camberwell collaborative psychosis study. Br J Psychiatry 1993; 162:65-71.
17. Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CT, et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry 1996; 153:1554-1563. A multislice technique allows simultaneous acquisition of proton spectra from multiple brain regions. Significant reductions in NAA/creatine and NAA/choline were found bilaterally in hippocampus and dorolateral prefrontal cortex but not in other brain areas.
18. Stanley J, Williamson PC, Drost DJ, Rylett RJ, Carr TJ, Malla A, et al. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull 1996; 22:597-609.
19. Rapaport J, Giedd J, Kumra S, Jacobsen L, Smith A, Lee P, et al. Childhood-onset schizophrenia-progressive ventricular change during adolescence. Arch Gen Psychiatry 1997; 54:897-903. This study presents the strongest evidence to date that progressive enlargement of the lateral ventricles occurs for some period of time after the onset of schizophrenia. Although it remains uncertain whether this finding can be generalized to patients with adult-onset schizophrenia, other recent work by this group supports the view that childhood-onset and adult-onset schizophrenia are the same illness or illnesses.
20. DeLisi L, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res Neuroimag 1997; 74:129-140.
21. Nair T, Christensen JD, Kingsbury SJ, Kumar NG, Terry WM, Garver DL. Progression of cerebroventricular enlargement and the subtyping of schizophrenia. Psychiatry Res Neuroimag 1997; 74:141-150.
22. McGuire P, Shah GM, Murray RM. Increased blood flow in Broca's area during auditory hallucinations in schizophrenia. Lancet 1993; 342:703-706.
23. Silbersweig D, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, et al. A functional neuroanatomy of hallucinations in schizophrenia. Nature 1995; 378:176-179.
24. David A, Woodruff PWR, Howard H, Mellers JDC, Brammer M, Bullmore E, et al. Auditory hallucinations inhibit exogenous activation of auditory association cortex. NeuroReport 1997; 7:932-936.
25. McGuire P, Silbersweig DA, Wright I, Murray RM, Frackowiak RS, Frith CD. The neural correlates of inner speech and auditory verbal imagery in schizophrenia: relationship to auditory verbal hallucinations. Br J Psychiatry 1996; 169:148-159. The authors compared three different groups of individuals (patients with a history of hallucination, those with no history of halluciations and normal control individuals) under three different conditions (silent inner speech, imagining a spoken word and a control task). Patients with hallucinations showed a failure to activate regions implicated in the monitoring of inner speech.
26. Frith CD, Done DJ. Towards a neuropsychology of schizophrenia. Br J Psychiatry 1988; 153:437-443.
27. Malhotra A, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17:141-150.
28. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997; 154:805-811. This is a PET study that demonstrated that ketamine-induced psychosis was associated with a selective activation of the prefrontal cortex.
29. Vollenweider F, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and (18F)-fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997; 7:9-24.
30. Vollenweider F, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 1997; 7:25-38. The S-isomer but not the R-isomer of ketamine was associated with frontal and thalamic activation as well as induction of psychopathology. The comparison of isomers shows itself to be a very compelling method for delineating causal relationships.
31. Vollenweider F, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 1997; 16:357-372. Psilocybin was used to induce psychotic symptoms and was associated with metabolic hyperfrontality. The same group has reported metabolic hyperfrontality with ketamine-induced psychosis. Converging evidence from different challenges that induce broadly similar psychopathology helps focus on the metabolic changes that might be more central to the manifestation of psychosis.
32. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, Hall H, et al. G. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 1990; 47:213-219.
33. Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehikoinen P, Ruotsalainen U, et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 1994; 51:116-123.
34. Wong DF, Pearlson GD, Tune LE, Young LT, Meltzer CC, Dannals RF, et al. Quantification of neuroreceptors in the living human brain 4. Effect of aging and elevations of D-2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab 1997; 17:331-342.
35. Wong DF, Wagner HNJ, Tune LE, Dannals RF. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234:1558-1563.
36. Andreasen N, Carson R, Diksic M, Evans AC, Farde L, Gjedde A, et al. Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum. Schizophr Bull 1988; 14:471-484.
37. Nordstrom A, Farde L, Eriksson L, Halldin C. No elevated d-2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and (c-11)n-methylspiperone. Psychiat Res Neuroimag 1995; 61:67-83.
38. Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, et al. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 1997; 25:1-14.
39. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, De-Souza CD, Erdos J, et al. Single photon emission computed tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996; 93:9235-9240. Endogenous dopamine displaces the ligand iodobenzamide from its binding to dopamine receptors. The amphetamine-induced displacement of iodobenzamide in patients with schizophrenia was statistically higher than in control individuals suggesting that patients may have a dysregulation of presynaptic dopamine release. This ability to assess endogenous transmitter, and its particular application in concert with a pharmacological challenge, is likely to become an important new functional imaging paradigm.
40. 11C]raclopride and PET. The authors validate the technique by direct experiments in baboons where both the PET and microdialysis studies were done simultaneously.
41. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544.
42. Kapur S, Remington G, Jones C, Wilson AA, DaSilva J, Houle S, et al. High levels of dopamine D2 receptor occupancy with low dose haloperidol treatment: a PET study. Am J Psychiatry 1996; 153:948-950. A clinical study in first episode patients which attempts to apply the receptor occupancy concepts in a clinical context. The results buttress the argument for use of neuroleptics in doses much lower than have been used in previous studies.
43. Kapur S, Zipursky RB, Roy P, Jones C, Remington G, Reed K, et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology 1997; 131:148-152.
44. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Arch Gen Psychiatry 1991; 48:739-745.